A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

Dey Pharma

Status and phase: Completed; Phase 3

Conditions: COPD

Treatments: Drug: Tiotropium Bromide; Drug: Formoterol Fumarate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00308191

201-070

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Medical diagnosis of COPD
• Current or prior history of cigarette smoking

Exclusion criteria

• Medical diagnosis of asthma
• Significant condition or disease other than COPD

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind